Education
About Us
Working with TipRanks
Follow Us
Prenetics Group (PRE)
NASDAQ:PRE
PRE Stock Chart & Stats
$16.91
-$0.22(-3.97%)
At close: 4:00 PM EST
$16.91
-$0.22(-3.97%)
Day’s Range― - ―
52-Week Range$3.09 - $22.86
Previous CloseN/A
Volume5.03K
Average Volume (3M)138.91K
Market Cap
$284.57M
Enterprise Value$207.72M
Total Cash (Recent Filing)$61.49M
Total Debt (Recent Filing)$2.20M
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Jun 08, 2026EPS Estimate
-0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.77
Shares Outstanding15,247,465
10 Day Avg. Volume156,144
30 Day Avg. Volume138,906
Financial Highlights & Ratios
PEG Ratio-0.27
Price to Book (P/B)1.27
Price to Sales (P/S)2.40
P/FCF Ratio-10.05
Enterprise Value/Market Cap0.73
Enterprise Value/Revenue2.18
Enterprise Value/Gross Profit4.12
Enterprise Value/Ebitda-5.07
Forecast
1Y Price Target
$36.00Price Target Upside112.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.51
Revenue Forecast (FY)$180.71M
Bulls Say, Bears Say
Bulls Say
Rapid IM8 Revenue ScaleIM8’s rapid climb to a $120M ARR in under a year signals durable product-market fit and scalable recurring revenue. A fast-ramping core brand reduces time-to-scale, enables operating leverage across fixed costs, and provides a predictable base to fund international expansion and clinical validation.
High And Improving Gross MarginsSustained gross margins near 60% reflect structurally favorable unit economics for IM8’s testing/subscription model. High product margins create a buffer for marketing spend while enabling margin expansion as scale rises, making path-to-operating profitability more achievable if topline growth persists.
Strong Liquidity & Low LeverageAbout $171M of adjusted liquid assets and no debt provide multi‑quarter runway to invest in growth, fund clinical trials, and execute international rollouts without immediate refinancing. The proceeds from recent divestitures materially lower solvency risk during the scale-up phase.
Bears Say
Multi-year Cash BurnPersistent negative operating and free cash flow signals ongoing cash burn to fund growth; until sustained positive cash generation occurs, the company depends on existing liquidity or future capital. This raises execution risk if growth or margin targets slip and extends the timeline to self-sufficiency.
Revenue Concentration In IM8With roughly two‑thirds of revenue tied to IM8, the firm faces concentration risk: brand, competitive, or regulatory setbacks to IM8 would materially impair results. Durable growth assumes successful geographic/product diversification; execution failures could rapidly erode top-line momentum.
Marketing-Intensive Model And CAC HistoryHistorically negative unit economics in 2025 required repricing and subscription changes to restore profitability. Continued dependence on heavy, scalable marketing creates execution and CAC volatility risk; sustained efficient customer acquisition is essential to convert strong gross margins into lasting operating profits.
Prenetics Group News
PRE FAQ
What was Prenetics Group’s price range in the past 12 months?
Prenetics Group lowest stock price was $3.09 and its highest was $22.86 in the past 12 months.
What is Prenetics Group’s market cap?
Prenetics Group’s market cap is $284.57M.
When is Prenetics Group’s upcoming earnings report date?
Prenetics Group’s upcoming earnings report date is Jun 08, 2026 which is in 100 days.
How were Prenetics Group’s earnings last quarter?
Prenetics Group released its earnings results on Feb 18, 2026. The company reported -$1.77 earnings per share for the quarter, missing the consensus estimate of -$0.33 by -$1.44.
Is Prenetics Group overvalued?
According to Wall Street analysts Prenetics Group’s price is currently Undervalued.
Does Prenetics Group pay dividends?
Prenetics Group pays a Quarterly dividend of $0.7 which represents an annual dividend yield of N/A. See more information on Prenetics Group dividends here
What is Prenetics Group’s EPS estimate?
Prenetics Group’s EPS estimate is -0.62.
How many shares outstanding does Prenetics Group have?
Prenetics Group has 15,247,465 shares outstanding.
What happened to Prenetics Group’s price movement after its last earnings report?
Prenetics Group reported an EPS of -$1.77 in its last earnings report, missing expectations of -$0.33. Following the earnings report the stock price went down -7.728%.
Which hedge fund is a major shareholder of Prenetics Group?
Currently, no hedge funds are holding shares in PRE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Prenetics Group Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$36.00 (112.89% Upside)
$36.00 (112.89% Upside)
Blogger Sentiment
Bullish
PRE Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
225.59%
12-Months-Change
Fundamentals
Return on Equity
-23.93%
Trailing 12-Months
Asset Growth
-16.65%
Trailing 12-Months
Company Description
Prenetics Group
Prenetics Global Limited, an investment holding company, operates as a diagnostics and genetic testing company. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring system that allows users to take COVID-19 tests at point-of-care or at home utilizing the nucleic acid amplification test. The company's products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; Circle Medical, a diagnostic testing product; and Circle One and F1x/Fem. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.
PRE Company Deck
PRE Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a strongly positive operational and financial transformation driven by IM8: exceptional top-line growth (FY revenue +480% YoY), rapid product-market fit (IM8 $120M run rate), improving gross margins (~59% consolidated; IM8 63%), healthy unit economics (LTV:CAC ~3x; payback ~3.4 months) and a fortified balance sheet (~$171M liquidity, 0 debt). Near-term risks include ongoing adjusted EBITDA losses with FY2026 guidance widening to $16M–$20M as the company invests to scale, revenue concentration in IM8 (~65% of FY2025 revenue), historical CAC inefficiency in 2025, reliance on intensive marketing spend, and residual crypto exposure. Overall, the positive growth trajectory, margin profile, and strong liquidity substantially outweigh the near-term profitability and concentration risks.View all PRE earnings summariesPRE Stock 12 Month Forecast
Average Price Target
$36.00
▲(112.89% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.04% Mutual Funds
6.61% Other Institutional Investors
93.12% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---